Sociedad Americana de Hirudoterapia

Tanzania Medicines and Medical Devices Authority

TMDA · Tanzania · africa

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Tanzania's Medicines and Medical Devices Authority — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national medical device framework or traditional-medicine pathways as appropriate.

Regulatory Profile

Agency type
national regulator
Region
africa
Country
Tanzania
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Tanzania Medicines and Medical Devices Act, Cap 219 (Revised Edition)
  • Tanzania Traditional and Alternative Medicines Act, 2002

Prescriber Requirements

  • Medical Council of Tanganyika–registered physician — order required for any biomedical device application
  • Traditional and alternative medicine practitioners registered under the Traditional and Alternative Medicines Council may have separate scope; specific hirudotherapy authorisation not independently verified by ASH

Supply Chain & GMP

TMDA registration as applicable; English and Kiswahili-language labelling. Standard cold-chain conditions.

Import/Export Rules

TMDA import authorisation; Ministry of Livestock and Fisheries / veterinary services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes (NHIF) for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. TMDA is a WHO-listed Maturity Level 3 regulator for medicines (East African Community harmonisation); whether this maturity extends to live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.